Neuroblastoma spreads through an unusually aggressive combination of mechanisms rooted in its embryonic origins, amplified by genetic aberrations like MYCN and ALK, and sustained by the tumor’s ability to reshape distant tissue into hospitable ground. As the most common and deadliest cancer of infancy, neuroblastoma arises from cells of the neural crest, a population of migratory embryonic cells that already possess the molecular machinery to travel through the body. When those cells become cancerous and retain or reactivate that migratory program, the result is a tumor with a built-in capacity for dissemination that most adult cancers must evolve from scratch.
Neural Crest Origins and Built-In Migratory Capacity
To understand why neuroblastoma metastasizes the way it does, you need to appreciate where it comes from. Neural crest cells are a transient population that emerges early in embryonic development and migrates extensively throughout the body, eventually giving rise to the sympathetic nervous system, parts of the adrenal glands, pigment cells, and portions of the facial skeleton. Neuroblastoma arises from precursor cells of the sympathetic nervous system that fail to differentiate properly, leaving them stuck in a proliferative, immature state.1PubMed Central. The connections between neural crest development and neuroblastoma Because of this lineage, tumors can appear anywhere along the path that neural crest cells travel during normal development, though they most often arise in the adrenal glands or alongside the spinal ganglia.2PubMed Central. Recent advances in the developmental origin of neuroblastoma: an overview
This embryonic heritage matters for metastasis because neural crest cells are, by nature, migratory. They rely on molecular signals involving cell adhesion, cytoskeletal remodeling, and matrix interactions to move through developing tissue. When those same pathways become dysregulated in a tumor context, the cells are already equipped with the basic tools to invade surrounding tissue and enter the bloodstream. This is a fundamental difference from many adult carcinomas, which must undergo extensive reprogramming to acquire migratory ability. Neuroblastoma cells, in a sense, never fully lost it.3PubMed Central. Neuroblastoma-A Neural Crest Derived Embryonal Malignancy
MYCN Amplification as a Central Driver
If neural crest origins provide the migratory hardware, MYCN amplification provides the accelerator. MYCN is an oncogene that, when present in extra copies in the tumor’s DNA, correlates strongly with high-risk metastatic disease and poor prognosis.4PubMed Central. Metastasis in neuroblastoma: the MYCN question Roughly a quarter of neuroblastoma cases carry MYCN amplification, and these tumors behave very differently from their non-amplified counterparts: they grow faster, resist treatment more stubbornly, and spread more widely.
MYCN drives metastasis through several downstream effects. One well-characterized mechanism involves the suppression of a surface protein called CD9. In a transgenic mouse model, researchers found that MYCN, working together with the enzyme HDAC5, directly binds to the CD9 gene’s control region and silences it. CD9 normally acts as a brake on invasion, so turning it off unleashes the cell’s ability to migrate and invade distant tissues. CD9 expression dropped as tumors progressed in these mice, and in human neuroblastomas without MYCN amplification, the same gene was silenced through a different route, chemical modification of its DNA, with heavy silencing linked to advanced-stage disease.5PubMed Central. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma
MYCN also rewires the cell’s metabolism to sustain rapid growth and proliferation. It increases uptake and breakdown of nutrients, ramps up production of the building blocks cells need to divide, and boosts energy output. This metabolic reprogramming is not separate from the metastatic program; it fuels the enormous energy demands of cells that are simultaneously proliferating and migrating. For patients with MYCN-amplified neuroblastoma, the overall survival rate remains below 50% even with the most intensive treatments available.6PubMed Central. MYCN and Metabolic Reprogramming in Neuroblastoma
ALK Mutations and Cytoskeletal Rewiring
ALK, or anaplastic lymphoma kinase, is the other major genetic driver in neuroblastoma. When mutated or overactivated, ALK promotes proliferation and migration while simultaneously blocking normal differentiation, keeping cells in a dangerously immature state.7PubMed Central. Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer ALK mutations are found in both inherited and sporadic neuroblastoma cases, and they often co-occur with other high-risk features.
What makes ALK especially relevant to dissemination is its connection to the cell’s internal skeleton. Research has shown that ALK regulates GSK3, an enzyme involved in cytoskeletal dynamics, the internal scaffolding that cells use to move. By phosphorylating GSK3 in an unusual way, ALK may alter which proteins GSK3 acts upon, potentially changing how the cell physically reshapes itself to crawl through tissue.8PubMed Central. ALK and GSK3: Shared Features of Neuroblastoma and Neural Crest Cells This connects back to the neural crest theme: ALK uses the same machinery that normal neural crest cells employ during embryonic migration, but without the developmental signals that would eventually tell those cells to stop.
Telomere Maintenance as a Gatekeeper of Aggressiveness
Beyond MYCN and ALK, a third genetic axis defines high-risk neuroblastoma: telomere maintenance. Whole-genome sequencing of neuroblastomas revealed that genomic rearrangements near the TERT gene, which encodes an enzyme that maintains chromosome ends, occur in roughly a quarter to a third of high-stage tumors. These rearrangements were found only in high-risk cases, never in low-risk ones, and they defined a subgroup with particularly poor outcomes.9PubMed Central. Telomerase activation by genomic rearrangements in high-risk neuroblastoma
What emerged from this work is a picture of three nearly non-overlapping categories of high-risk neuroblastoma. About 37% have MYCN amplification, about 23% have TERT rearrangements, and about 11% carry ATRX deletions, which enable an alternative telomere-lengthening mechanism. Each category carries poor prognosis, and all three converge on the same functional result: the cell’s telomeres are maintained, granting the tumor indefinite replicative potential.10PubMed. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors In MYCN-amplified tumors, TERT is also upregulated. The takeaway is that whatever the specific genetic event, a high-risk neuroblastoma cell has found a way to keep dividing indefinitely, a prerequisite for successful metastatic colonization of distant sites.
How Cells Actually Leave the Primary Tumor
The physical process of dissemination involves molecular programs that loosen cell-cell adhesion and increase the cell’s ability to invade surrounding tissue. In many cancers, this process is described using the framework of epithelial-to-mesenchymal transition, though neuroblastoma cells are not epithelial in origin. Nevertheless, they use analogous programs. The signaling molecule Nodal, for example, increases levels of the transcription factor Zeb1 in neuroblastoma cells, and Zeb1 is a well-known driver of this invasive switch. When researchers knocked down Zeb1, the pro-metastatic effects of Nodal were blunted.11PubMed. Nodal increases the malignancy of childhood neuroblastoma cells via regulation of Zeb1
Neuroblastoma cells also communicate at a distance before they physically arrive at metastatic sites. Extracellular vesicles, tiny membrane-enclosed packages that cells shed into the bloodstream, appear to play a role in preparing distant tissues for tumor colonization. In a zebrafish model, vesicles released by neuroblastoma cells that had been grown under low-oxygen conditions were particularly effective at promoting metastatic outgrowth. When these hypoxic vesicles were injected before tumor cells arrived, the subsequent cancer cells proliferated more aggressively than when normoxic vesicles were used.12PLOS ONE. Neuroblastoma-derived hypoxic extracellular vesicles promote metastatic dissemination in a zebrafish model This suggests the primary tumor can condition distant tissue, creating what researchers call a pre-metastatic niche, even before a single cancer cell arrives there.
Adrenergic and Mesenchymal Cell States
Within a single neuroblastoma tumor, cells can exist along a spectrum between two broad phenotypes: adrenergic (more differentiated, resembling developing sympathetic neurons) and mesenchymal (more stem-like and migratory). Early research suggested that tumor cells readily switch between these states in response to chemotherapy, with the mesenchymal state being more drug-resistant. If true, that would mean treatment itself could drive cells toward a metastasis-prone state.
More recent modeling, however, suggests the picture is more nuanced. A 2024 study found that the best explanation for treatment response patterns was not that individual cells switch between states, but rather that adrenergic and mesenchymal cells behave as two distinct populations with different rates of proliferation and survival. Under treatment, the composition of the tumor shifts because one population is killed off faster than the other, not because cells are transforming.13PubMed Central. Cell types or cell states? An investigation of adrenergic and mesenchymal cell phenotypes in neuroblastoma This distinction matters therapeutically because the right treatment strategy depends on whether you are trying to prevent a switch (which implies you might intercept the transition) or trying to kill a resistant subpopulation (which requires a drug that can target it directly).
Bone Marrow as the Preferred Destination
Neuroblastoma metastasizes most frequently to the bone marrow, liver, and bone cortex. Bone marrow is the most clinically significant site, partly because of its frequency and partly because marrow involvement is associated with therapy resistance and relapse. Single-cell analyses of metastatic bone marrow from neuroblastoma patients have begun to explain why the marrow is so hospitable.
Tumor cells arriving in the marrow express signals, including CD24, VEGFA, and Notch pathway ligands like DLL3 and DLK1, that actively reshape the local immune environment. CD24 on tumor cells interacts with an inhibitory receptor on macrophages, helping the cancer evade immune attack. Meanwhile, Notch ligands from the tumor appear to recruit and reprogram neutrophils and macrophages within the marrow, converting them from potential anti-tumor defenders into tumor-supporting accomplices.14The Journal of Clinical Investigation. Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature Separately, neuroblastoma cells signal to the marrow microenvironment via macrophage migration inhibitory factor and midkine, rewiring monocytes into hybrid cells that display both inflammatory and anti-inflammatory features, resembling tumor-associated macrophages.15PubMed Central. Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis
This immune reshaping is not a minor side effect; it is central to the metastatic process. Tumor-associated macrophages with a pro-tumor phenotype predict poor clinical outcomes in neuroblastoma and contribute to immunosuppression, promote further metastasis, and undermine radiation and immunotherapy responses.16PubMed Central. “Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
How Neuroblastoma Evades Immune Surveillance
Even before reaching the marrow and corrupting local immune cells, neuroblastoma cells deploy multiple strategies to avoid immune destruction in the bloodstream and at metastatic sites. Two of the best-characterized mechanisms involve downregulating the molecular flags that immune cells use to identify targets. First, tumor cells reduce their surface expression of HLA class I molecules, the tags that cytotoxic T cells read to recognize a cell as abnormal. Second, they lower levels of the activating ligands that natural killer cells depend on to trigger an attack.17PubMed. Mechanisms of immune evasion of human neuroblastoma The combined effect is that neuroblastoma cells become partially invisible to both arms of the immune system’s surveillance network. For a cell traveling through the blood and trying to seed a new tumor at a distant site, this is a critical survival advantage.
Circulating Tumor Cells and What They Reveal
Detecting disseminated neuroblastoma cells in the blood, known as circulating tumor cells, has become possible with increasingly sophisticated techniques. In one study using single-cell sequencing, researchers isolated neuroblastoma-specific cells from the blood of eight out of ten patients at diagnosis and three of four patients at relapse, with more cells detected in advanced-stage disease. The circulating cells carried the same genetic alterations as the primary tumor, including MYCN amplification and, in one case, a specific ALK mutation. Gene expression analysis revealed that these traveling cells had ramped up genes involved in blood vessel formation and cell division.18PubMed Central. Single-cell next-generation sequencing of circulating tumor cells in patients with neuroblastoma
An intriguing finding was that circulating cells from a single patient could be divided into distinct subgroups with different gene expression profiles, one more proliferative than the other. This heterogeneity among traveling cells hints that the metastatic process is not a single program but a spectrum, with different circulating cells potentially having different fates upon arriving at distant sites.
Liquid Biopsy for Tracking Disseminated Disease
Beyond counting whole circulating cells, researchers are now analyzing fragments of tumor DNA that float freely in the blood, called circulating tumor DNA. This approach has shown particular promise for monitoring neuroblastoma without repeated biopsies. In a study using personalized ctDNA panels, levels at diagnosis correlated with risk group and dropped steadily during effective treatment. All patients who remained disease-free tested negative for ctDNA during follow-up, while all four relapses in the cohort were accompanied by rising ctDNA. In one patient, ctDNA turned positive 78 days before the relapse was detected by standard clinical methods and then climbed over a thousandfold before additional treatment began.19PubMed Central. Personalized circulating tumor DNA analysis for sensitive disease monitoring and detection of relapse in neuroblastoma
Serial ctDNA profiling also captures how the tumor’s genetics evolve over time. In a study of high-risk patients, actionable genetic changes, including ALK and RAS-pathway variants, were identified in the majority of evaluable patients, and serial sampling detected disease evolution in nearly all patients who had a recurrently identified variant. In some cases, ctDNA confirmed disease progression before standard surveillance methods flagged it.20PubMed Central. Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma Separately, a technique quantifying unique TERT rearrangement breakpoints in ctDNA has improved therapy-response assessment and early relapse detection in individual patients, requiring as little as one nanogram of cell-free DNA from a blood sample.21Cancer Research Communications. Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma
Targeting the Drivers Therapeutically
Understanding the genetic and molecular drivers of dissemination has opened several therapeutic avenues. Anti-GD2 immunotherapy targets a sugar-fat molecule on the tumor cell surface and has improved survival for patients in their first remission. It is now increasingly used for relapsed or chemotherapy-resistant neuroblastoma, and newer engineered antibody constructs, natural killer cell approaches, and vaccines targeting GD2 are in development.22PubMed Central. Anti-GD2 immunotherapy for neuroblastoma Anti-GD2 monoclonal antibodies have only recently become standard of care for high-risk patients, despite decades of study.23PubMed Central. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma
For tumors driven by ALK mutations, a growing toolkit of inhibitors now exists. Crizotinib, the first ALK inhibitor tested in neuroblastoma, showed effectiveness but often encountered resistance over time. Ceritinib serves as an alternative when crizotinib fails. Lorlatinib, a more potent next-generation inhibitor, works against multiple ALK mutation types, including those resistant to earlier drugs. Newer agents like repotrectinib have shown promise in early studies, particularly when combined with chemotherapy.24PubMed Central. Integration of ALK gene mutations and targeted therapies in pediatric high-risk neuroblastoma: advancements in precision oncology
MYCN itself has long been considered “undruggable” because it is a transcription factor without an obvious binding pocket for a small molecule. Researchers have instead pursued indirect strategies. BET bromodomain inhibitors suppress MYCN gene expression by interfering with the molecular machinery that reads its promoter, leading to growth arrest and cell death in MYCN-amplified neuroblastoma models and a significant survival advantage in three animal models.25PubMed Central. Targeting MYCN in neuroblastoma by BET bromodomain inhibition Another approach exploits a vulnerability that MYCN amplification creates: these tumor cells are primed for programmed cell death because MYCN simultaneously drives both pro-growth and pro-death signals. Combining a BCL-2 inhibitor with an Aurora Kinase A inhibitor triggered widespread tumor cell death in MYCN-amplified models and achieved complete tumor regression in several cases, including a patient-derived xenograft model.26PubMed Central. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
Preclinical Models That Mirror Human Metastasis
Studying metastasis in the lab requires models that faithfully recapitulate how the disease behaves in children. Patient-derived orthotopic xenografts, in which tumor tissue from a high-risk patient is implanted into a corresponding anatomical site in an immunodeficient mouse, have proven to be the most clinically relevant approach. These models retain the genetic and phenotypic features of the original patient tumor and, critically, reproduce its metastatic patterns.27PubMed Central. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours The tumor microenvironment that develops in these mice mirrors the hallmarks of aggressive human neuroblastoma, including the stromal and immune cell features seen in patient tumors.28PubMed. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours
Detailed molecular characterization of one such xenograft derived from a stage 4 patient showed that it retained the high-risk features of the original tumor and exhibited aggressive growth and metastasis in the mouse.29PubMed Central. Development and characterization of a human orthotopic neuroblastoma xenograft These models are now considered essential for preclinical drug testing because they avoid the major pitfall of cell-line-based systems, which often lose the heterogeneity and microenvironmental interactions that drive real-world metastasis.
The Physical Microenvironment and Extracellular Matrix
Metastasis is not purely a story of genes and immune cells. The physical properties of the tissue surrounding a tumor also shape dissemination. In neuroblastoma, the extracellular matrix, the mesh of proteins and sugars that provides structural support to tissue, actively interacts with tumor cells through receptor-ligand connections. One such interaction involves vitronectin, a glycoprotein that acts as a bridge between the matrix and tumor cells, and its binding partners on the cell surface. Research in a clinical cohort and preclinical models established that this interaction correlates with the stiffness of the extracellular matrix in high-risk neuroblastoma.30International Journal of Pharmaceutics. Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma Stiffer matrix environments are associated with more aggressive cancer behavior across many tumor types, and in neuroblastoma this stiffness appears linked to specific integrin-mediated signaling that promotes cell spreading and migration. Understanding these biomechanical interactions could eventually open new therapeutic strategies that target the physical environment rather than the tumor cell itself.
Single-cell and spatial multi-omics technologies are now layering all of these dimensions together, revealing how genetic instability, epigenetic reprogramming, metabolic plasticity, immune remodeling, and stromal interactions cooperate within the same tumor to drive persistence and relapse.31PubMed Central. Dissecting neuroblastoma heterogeneity through single-cell multi-omics: insights into development, immunity, and therapeutic resistance These integrated views are pushing the field toward an appreciation that metastasis in neuroblastoma is not controlled by any single driver but by the convergence of multiple systems, each of which represents a potential point of therapeutic intervention.